BioSpace News Archive

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate virtually in a Fireside Chat at Barclays Global Healthcare Conference

Flexion Therapeutics, Inc. announced equity inducement grants to four new employees consisting of 14,565 restricted stock units.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 26,000 shares of the Company’s common stock with an exercise price of $5.05 per share, the closing price of Assembly Bio’s common stock on March 1, 2021.

Health Canada has suspended the product licence, which means the product can no longer legally be sold. All lots are being recalled due to potential safety issues.

Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2020 financial results

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies

Blueprint Medicines Corporation announced that, effective on March 1, 2021, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 15,474 shares of its common stock and an aggregate of 7,736 restricted stock units to nine new employees under Blueprint Medicines’ 2020 Inducement Plan.

Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, reported the grant of restricted stock units to acquire 40,800 shares of common stock to ten newly hired employees and stock options to purchase an aggregate of 55,000 shares of common stock to four such newly hired employees.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (“Regulus”), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Global Life Sciences Conference

Healthpeak Properties, Inc. (NYSE: PEAK) announced today that Tom Herzog, its Chief Executive Officer, is scheduled to present at the Barclays 2021 Global Healthcare Conference.